Pralsetinib bulk supplier for pharma manufacturers

Pralsetinib 100 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 100 mg

Reference Brands: Gavreto (USA/EU)

Pralsetinib is a selective RET (rearranged during transfection) kinase inhibitor used to treat cancers that harbor RET gene fusions or mutations. It is administered orally and represents a targeted therapy for certain non-small cell lung cancers and thyroid cancers with RET alterations.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Pralsetinib — third party manufacturing & bulk supply

Pralsetinib 100 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Pralsetinib is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Pralsetinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Pralsetinib →

Back to Listing

Frequently Asked Questions

Pralsetinib is used for the treatment of non-small cell lung cancer (NSCLC) and thyroid cancers that have a rearranged during transfection (RET) gene alteration. It works as a selective RET kinase inhibitor, blocking the activity of abnormal RET proteins that drive cancer cell growth.

Pralsetinib is made from the active ingredient pralsetinib, a small-molecule tyrosine kinase inhibitor specifically designed to target RET fusion–positive or RET-mutant cancers.

The trade name of Pralsetinib is Gavreto.

Pralsetinib (Gavreto) is developed and marketed by Blueprint Medicines in collaboration with Genentech (a member of the Roche Group).

The generic name is Pralsetinib.

The brand name is Gavreto.

Pralsetinib is manufactured in the United States and Switzerland by Blueprint Medicines and Roche facilities following international regulatory standards for oncology drugs.